Hepatitis C treatment guidelines Markets to 2019 - Market Shares, Strategies, and Forecasts Report Available Online By ResearchMoz.us

Hepatitis C treatment guidelines MarketsHepatitis C treatment guidelines Markets to 2019 - Market Shares, Strategies, and Forecasts Report Available Online By ResearchMoz.us PR Newswire ALBANY, New York, February 19, 2014 ResearchMoz.us includes new market research report "Hepatitis C Therapeutics in Major Developed Markets to 2019" to its huge collection of research reports. Researchmoz presents this most up-to-date research on Hepatitis C Therapeutics in Major Developed Markets to 2019 (http://www.researchmoz.us/hepatitis-c-therapeutics-in-major-developed- markets-to-2019-outstanding-recent-approvals-and-late-stage-pipeline-to- transform-clinical-and-commercial-landscape-report.html). GBI Research, has released the pharma report - "Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late- Stage Pipeline to Transform Clinical and Commercial Landscape". The current Hepatitis C treatment landscape consists of a combination of pegylated interferon, ribavirin and, in patients infected with genotype 1 hepatitis C, one of two direct-acting antiviral agents (DAAs). Products with these mechanisms of action have performed strongly in the commercial setting, with the market leader Incivek (a DAA) having reached blockbuster sales. However, these products are very poorly tolerated and only moderately efficacious.